Payer Policy Barriers in Migraine
What it is
Prior authorization requirements, step therapy mandates, and formulary restrictions create substantial barriers to CGRP-targeting therapies and other advanced migraine treatments. Nearly all CGRP monoclonal antibodies and gepants require prior authorization from commercial payers. Step therapy requirements — mandating failure of 2-4 older medications before approving newer targeted therapies — are nearly universal. These barriers delay effective treatment, increase clinician administrative burden, and disproportionately affect patients without the resources to navigate complex appeals processes.
How it works
The Vault payer policy database covers 1,205 payers across all 50 states (Q1 2026 data). Step therapy requirements for CGRP mAbs typically require demonstration of failure of 2-3 oral preventive medication classes. Formulary placement varies significantly by payer and formulary year. Clinicians spend an estimated 3-6 hours per CGRP PA submission on documentation, portal navigation, and appeals.
What patients need to know
When a doctor prescribes a migraine medication, your insurance company may require you to first try and fail other medications before they will approve the one your doctor recommended. This process can take months. The Headache Vault helps your doctor build the documentation needed to get these approvals.
Prior authorization
The full payer policy data is the core of the PA Engine. For advocacy, payer blocking is a systems-level argument: the aggregate burden of prior authorization requirements across 1,205 payers has quantifiable population-level effects on treatment access. HOH advocacy leverages this data to support Gold Card legislation, step therapy reform, and payer transparency requirements.
Dealing with a CGRP prior authorization?
The PA Engine has payer-specific step therapy requirements, denial codes, and appeal language for 1,205 payers across all 50 states. Free, no account required.
Run a PA →